Ulusal <strong>Kan</strong> <strong>Merkezleri</strong> <strong>ve</strong> <strong>Transfüzyon</strong> T›bb› Kursu XII - ‹leri Kurs KAYNAKLAR 1. Shander A, Capellini MD, Goodnough LT: ‹rono<strong>ve</strong>rload and toxicity: the hidden risk of multiple blood transfusions. Vox Sanguinis, 2009, 1-13. 2. Ozment CP, Turi JL: ‹rono<strong>ve</strong>rload following red blood cell transfusion and its impact on disease se<strong>ve</strong>rity. Biochimica et Biophysica Acta, 1990, 1790:694-701. 3. Duca L, Delbini P, nava I, vaja V, Fiorelli G, Capellini MD: Mutation analysis of hepcidin and ferroportin genes in Italian prospecti<strong>ve</strong> blood donors with iron o<strong>ve</strong>rload. Am J Hematol, 2009, 84(9):592-593. 4. Brissot P. Diagnosis and current treatments for primary iron o<strong>ve</strong>rload. Am J Hematol, 2007, 82:1140-1141. 5. Hershko C: Iron loading and its clinical implications. Am J Hematol, 2007, 82:1147-1148. 6. Novotny VMJ: Red cell transfusion in medicine: Future challenges. Transfusion Clinique et Biologique, 2007, 14:538-554. 7. Piga A. Filomeno L, Duca L, Roggero S, Vinciguerra T, Calabrese R, Hershko C, capellini MD: High non transferin boun iron le<strong>ve</strong>ls and heart disease in thalassemia major.Am J Hematol, 2009, 84:20-33. 8. Pietrangelo A: Iron chelation beyond transfusion iron o<strong>ve</strong>rload. Am J Hematol, 2007, 82:1142-1146. 9. Ameli M, beshaarti S, Nemati K, Zamani F. relationship between elevated li<strong>ve</strong>r enzyme with iron o<strong>ve</strong>rload and viral hepatitis in thalassemia major patients in Norhern Iran. Saudi Med. J, 2008, 29(11):1611-1615. 10. Vermylen C. What is new in iron o<strong>ve</strong>rload. Eur J Pediatr, 2008, 167:377-381. 11. Wood J: Diagnosis and management of transfusion iron o<strong>ve</strong>rload: the role of imaging. Am J Hematol,2007, 82:1132-1135. <strong>12</strong>. Ayd›nok Y: Talasemide demir yükü <strong>ve</strong> flelasyon (Editörler) Canatan D, Ayd›nok Y: Talasemi <strong>ve</strong> Hemoglobinopatiler: Tan› <strong>ve</strong> Tedavi. 2007 Antalya. sayfa:159-173. 13. Taher A, Musallam KM, El Rassi F, Duca L, ‹nati A, Koussa S, Capellini MD: Le<strong>ve</strong>ls of non transferin-bound iron as an index of iron o<strong>ve</strong>rload in patients with thalassemia intermedia. Br J Haematol, 2009, 146:569-572. 14. Ghugre Nr, Gonzalez-Gomez I, Butensky E, Noetzli L, Fischer R, Williams R, Harmatz P, Coates TD, Wood JC: pattern of hepatic iron distribution in patients with chronically transfused thalassemia and sickle cell disease. Am J Hematol, 2009, 84 :480- 483. 15. Callea F: Irono<strong>ve</strong>rload and chronicallay transfused patients: numbers, sacles and clinical research. Am J Hematol, 2009, 84:471- 472. 16. Flanagan JM, Steward S, Hankins JS, Howard TM, Neale G, Ware RE: Microaary analysis of li<strong>ve</strong>r gene expression in iron o<strong>ve</strong>rload patients with sickle cell anemia and beta thalassemia. Am J Hematol, 2009, 84(6):328- 334. 17. Porter J: Concepts and goals in management of transfusional iron o<strong>ve</strong>rload. Am J Hematol, 2007, 82:1136- 1139. 18. Mavrogeni S: Evaluation of myocardial iron o<strong>ve</strong>rload using magnetic resonance imaging. Blood Transfus. 2009, 7(3):183 -187. 19. Papakonstantinou O, Alexopoulou E, Econopoulos N, Benekos O, kattamis A, Kostaridou S, Ladis V, Efstathopoulos E, Gouliamos A, Kelekis NL: Assessment of iron distribution between li<strong>ve</strong>r, spleen, pancreas, bone marrow and myocardium by means of R2 relaxometry with MRI in patients with beta-thalassemia. J Magn Reson Imaging, 2009, 29(4):853-859. 20. Leung AW, Chu WC, Lam WW Lee V, Li CK: Magnetic rosonance imaging assessment of cardiac and li<strong>ve</strong>r iron load in transfusion dependent patients. Pediatr Blood Cancer, 2009, 17:1-6. 21. Capellini MD, Piga A. Current status in iron chelation in hemoglobinopathies. Curr Mol Med, 2008, 8(7):663- 674. 22. Galanello R: New advances in iron chelation Hematologica, 2008, 2(1):194-200. 23. Jabbour E, Garcia-Manero G, Taher A, <strong>Kan</strong>tarjian HM: Managing iron o<strong>ve</strong>rload in patients with myelodisplastic syndromes with oral deferasirox therapy. Oncologist, 2009, 14(5):489-496. - <strong>12</strong>8 -
Ulusal <strong>Kan</strong> <strong>Merkezleri</strong> <strong>ve</strong> <strong>Transfüzyon</strong> T›bb› Kursu XII - ‹leri Kurs 24. Wimazal F, Nösslinger T, Baumgartner C, Sperr WR, Pfeilstöcker M, Valent P: Deferasirox induces regression of iron o<strong>ve</strong>rload in patients with myelodysplastic syndromes. Eur J Clin In<strong>ve</strong>st, 2009, 39(5):406-411. 25. Kim KH, Kim JW, Rhee JY, Kim MK, Kim BS, Kim I, Bang SM, Yoon SS, Lee JS, Han KS,Park S, Kim BK:Cost analysis iron related complications in a single institue. Korean J Intern Med. 2009, 24(1):33-36. - <strong>12</strong>9 -
Change language